Coalition to Save Pure Files Proxy Documents With SEC, Urges Pure's Board to Set an Annual Meeting Date

The Coalition to Save Pure, a group of stockholders and director nominees that has nominated a slate of six individuals to replace the current board of directors of Pure Bioscience, Inc. PURE, today filed its preliminary proxy statement with the Securities and Exchange Commission. Pure owns the rights to silver dihydrogen citrate (SDC), an antibacterial, antiviral and antifungal technology.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!